Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination.
The effects of immunity to vaccinia virus on the efficiency of vaccination with a vaccinia recombinant virus were studied. In mice the efficiency and duration of the B-cell response to the recombinant gene product of a second vaccinia recombinant virus were suppressed for more than 9 months, i.e. practically lifelong. Antibody titres against the recombinant gene product were not only lower but also lasted for a shorter time. Thus, immunity to vaccinia virus may influence both the titre and duration of the antibody response induced by a second distinct vaccinia recombinant vaccine.
Kündig
T M
TM
Institute of Experimental Immunology, University of Zürich, Switzerland.
Kalberer
C P
CP
Hengartner
H
H
Zinkernagel
R M
RM
D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D001402:B-Lymphocytes / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D007074:Immunoglobulin G / Q000276:immunology; D007075:Immunoglobulin M / Q000276:immunology; D008217:Lymphocytic choriomeningitis virus / Q000276:immunology; D051379:Mice; D008811:Mice, Inbred DBA; D013997:Time Factors; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000494:pharmacology*; D014616:Vaccinia virus / Q000276:immunology*; D014721:Vesicular stomatitis Indiana virus / Q000276:immunology; D014764:Viral Proteins / Q000276:immunology; D014765:Viral Vaccines / Q000494:pharmacology*
D000914:Antibodies, Viral; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D014614:Vaccines, Synthetic; D014764:Viral Proteins; D014765:Viral Vaccines